OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab)

Stock Information for OncoSec Medical Incorporated

Loading

Please wait while we load your information from QuoteMedia.